Corporate Magazine 2012 - Boehringer Ingelheim

12THE MAIN COMPLICATIONS OF DIABETES3The risk of stroke in newly diagnosedtype 2 diabetes is more than doubled.4Microvascular damage to the retina fromdiabetes (diabetic retinopathy).People with diabetes are two to four timesmore likely to have cardiovascular disease.Damage to the kidney filtering systems fromdiabetes (diabetic nephropathy).Damage to the nerves from diabetes(diabetic neuropathy) is a leading cause offoot wounds and ulcers.TRAJENTA® AND JENTADUETO®Both drugs are labelled for thetreatment of type 2 diabetes.5Diabetes Alliance – Boehringer Ingelheimand Eli Lilly & CompanyBased on its own research programmes,Boehringer Ingelheim has identifiedseveral drug candidates from multiplenew drug classes with promising characteristics.We are clinically developing them inan alliance with Eli Lilly & Company.The first result from this pipeline is linagliptin(trajenta®), which was firstlaunched in 2011, also as the single-pillcombination linagliptin and metformin(jentadueto®), which was first launchedin 2012. The second compound is empagliflozin,which will be filed for registrationin 2013.TRAJENTA® – linagliptinLinagliptin belongs to the drug class ofDPP4-inhibitors.trajenta® has been approved very rapidlyin all major markets and approvalfor fixed-dose combinations with metformin(jentadueto®), or as add-on toinsulin treatment, was obtained in2012. It can also be administeredwithout dosage adjustment in patientswith impaired renal function, whichfrequently occurs in diabetic patients.CAROLINA® trialIn an unprecedented effort to determinethe long-term benefit in cardiovascularcomplications, BoehringerIngelheim has performed a large outcomestudy versus a representative ofthe sulfonylurea drug class, glimepiride,the CAROLINA® study.Linagliptin is currently the only DPP4-inhibitor which is compared to an activecomparator in a large outcomestudy, and the CAROLINA® study hascompleted enrollment. Large outcomestudies will determine the beneficialeffects of linagliptin with a level ofcertainty not available for any otheroral antidiabetic drug.EmpagliflozinEmpagliflozin represents a novel classof antidiabetic drugs, the SGLT2-inhibitors.56 Boehringer Ingelheim annual report 2012